Literature DB >> 32505044

Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017-2018: A cross-sectional study.

Douglas R Roehler1, Gery P Guy2, Christopher M Jones2.   

Abstract

BACKGROUND: Expansion of buprenorphine for opioid use disorder treatment is a core component of the opioid overdose epidemic response. The Comprehensive Addiction and Recovery Act (CARA) of 2016 authorized nurse practitioners (NPs) and physician assistants (PAs) to obtain a DATA-waiver to prescribe buprenorphine. The objectives of this study are to examine national- and county-level buprenorphine prescription dispensing, patterns by patient demographics and clinician specialty, and county-level characteristics associated with buprenorphine dispensing.
METHODS: Retrospective analysis of buprenorphine prescriptions dispensed from approximately 92% of all retail prescriptions in the US (2017-2018). Analyses include rates of buprenorphine prescriptions dispensed, by patient demographics and prescriber specialty, changes in buprenorphine prescriptions dispensed at the national- and county-level, and county-level characteristics associated with buprenorphine dispensing.
RESULTS: Buprenorphine prescriptions dispensed increased by 9.1% nationally, from 40.7-44.4 per 1000 residents. From 2017 to 2018, NPs (351.9%) and PAs (257.3%) had the largest percent increases in dispensed buprenorphine prescriptions, accounting for 79.6% of the total increase. In 2018, county-level characteristics associated with high buprenorphine dispensing included. among others: greater potential buprenorphine treatment capacity, higher drug overdose death rates, and higher rates of Medicaid enrollment. Rural counties were associated with low buprenorphine dispensing.
CONCLUSION: Buprenorphine dispensing rates increased in the US from 2017 to 2018, suggesting the addition of NPs and PAs by CARA has contributed to an increase in dispensed buprenorphine prescriptions. Published by Elsevier B.V.

Entities:  

Keywords:  Buprenorphine; Opioid use disorder; Policy

Year:  2020        PMID: 32505044     DOI: 10.1016/j.drugalcdep.2020.108083

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  7 in total

1.  Methodological Challenges and Proposed Solutions for Evaluating Opioid Policy Effectiveness.

Authors:  Megan S Schuler; Beth Ann Griffin; Magdalena Cerdá; Emma E McGinty; Elizabeth A Stuart
Journal:  Health Serv Outcomes Res Methodol       Date:  2020-11-12

2.  The effect of Medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States.

Authors:  Hannah K Knudsen; Jeanie Hartman; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2022-01-29       Impact factor: 4.492

3.  Low-dose Buprenorphine Initiation in Hospitalized Adults With Opioid Use Disorder: A Retrospective Cohort Analysis.

Authors:  Dana Button; Jennifer Hartley; Jonathan Robbins; Ximena A Levander; Natashia J Smith; Honora Englander
Journal:  J Addict Med       Date:  2022 Mar-Apr 01       Impact factor: 3.702

4.  Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US.

Authors:  Beth Han; Christopher M Jones; Emily B Einstein; Wilson M Compton
Journal:  JAMA Netw Open       Date:  2021-10-01

5.  Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.

Authors:  Barbara Andraka-Christou; Cory Page; Victoria Schoebel; Jessica Buche; Rebecca L Haffajee
Journal:  Addict Sci Clin Pract       Date:  2022-08-09

6.  The Association Between Scope of Practice Regulations and Nurse Practitioner Prescribing of Buprenorphine After the 2016 Opioid Bill.

Authors:  Thuy Nguyen; Ulrike Muench; Barbara Andraka-Christou; Kosali Simon; W David Bradford; Joanne Spetz
Journal:  Med Care Res Rev       Date:  2021-04-01       Impact factor: 3.929

7.  The impact of CARA mandates on nurse practitioner controlled substance prescribing in Oregon: a cohort study.

Authors:  Tracy A Klein; Daniel Hartung; Sheila Markwardt
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-01-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.